Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Cripto-1 expression increases the expression of TNF-alpha in CD4+ T cells in tissues affected by chronic inflammatory disease. More
Nanoparticles that exhibit high epithelial uptake and transepithelial transport More
A novel adjuvant technology for use in vaccines and in antibody production that gives excellent immune responses with low manufacturing costs, and can be administered by a variety of routes More
Methods and formulations for treating or preventing Vascular Cognitive Impairment (VCI) through mucosal administration of E-selectin, an inducible adhesion molecule on endothelial cells More
Genetic cloning and sequencing of a novel IL-17 receptor-related gene More
Biomimic prenatal and postnatal maternal-to-infant transfer of clinical monosaccharides for improved neurologic development and immunologic functions More
Cancer immunotherapy using dendritic cells, and iii) Camel recombinant antibodies for FoxP3, Mucl & CEA. More
New methods of diagnosing and monitoring the progression or response to therapy of subjects with autoimmune hepatitis More
NexACT(R) utilizes highly effective, novel excipients or “penetration enhancers” to dramatically improve absorption and bioavailability of drugs. Varying the concentration of the enhancer allows for local or systemic delivery of drug, as desired. More
In order to, to achieve the most active action of body energy, it is known that pH of water-containing blood should be maintained at an alkaline of 7.35 to 7.45. More
Related Reports
Market Research Reports provided by reports.innovaro.com
May 2011 - 15 pages - $250
Dec 2010 - 37 pages - $500
Jan 2010 - $75
Jan 2011 - 34 pages - $500
Nov 2010 - 40 pages - $500
May 2011 - 15 pages - $250
Apr 2011 - 75 pages - $3,800
Dec 2010 - 22 pages - $500
Oct 2011 - 113 pages - $2,795
Jul 2011 - 136 pages - $500
Your selection
- Therapeutic target
- Immune related disorders del
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Adoptive immunotherapy
- Amyloidosis
- Autoimmune disease (non-specific)
- Chronic fatigue syndrome
- Chronic granulomatous disease
- Chronic immunosuppression
- Gout
- Graft versus host disease
- HIV/AIDS
- Immune disorder (non-specific)
- Immune thrombocytopenic purpura
- Immunomodulation
- Immunostimulation
- Immunosuppression
- Lupus erythematosis
- Myalgic encephalomyelitis
- Myasthenia gravis
- Neoplastic disease
- Organ transplant rejection
- Rheumatoid arthritis
- Servere combined immunodeficency
- Sjogren's syndrome
- Systemic sclerosis
- Transplant rejection
- Xenotransplantation
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us